MORRISVILLE, N.C., August 20, 2020 – Myocardial Solutions, Inc. (“MSI”) was recognized as the Most Innovative Cardiology Software Company of 2020. The award to MSI was published in Acquisition International’s (“AI Global”) annual Global Excellence Awards issue for the month of August. AI Global is a magazine publisher based in the U.K. and focuses on bringing its readers the latest news about innovative businesses worldwide.
The article speaks about MSI’s mission and the immense clinical value of MyoStrain® to address unmet cardiac and cancer care markets. As part of a critical solution to help cancer centers protect and manage cancer patients and survivors, MyoStrain becomes a key differentiator for centers to provide consistent care across chains and elevate the current standard of cancer care.
AI Global said: “This test could transform cardiac and cancer care by allowing physicians to detect segmental heart dysfunction and initiate early, preventative treatment long before cardiac symptoms occur.”
Peter Gaccione, President at MSI, commented: “MyoStrain addresses a growing concern in cardio-oncology and cancer, as there are millions of cancer patients and survivors who are at a significantly higher risk of developing cardiovascular disease but are not currently being monitored for signs of cardiotoxicity. MyoStrain seeks to overcome this burden by offering a holistic and patient-centric approach to helping cancer centers provide cardio-protective care to their patients.”
This specialized and prevention-focused approach to care represents a major stride in advancing the new and emerging cardio-oncology field, bridging the efforts of oncologists and cardio-oncologists to meet the needs of cancer patients. Through MyoStrain, MSI’s role will be to provide the information physicians need to potentially improve patient longevity and quality of life without interrupting the cancer treatment.
View MSI’s article in AI Global’s Excellence Awards magazine issue here.
Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.
To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.